Lampalizumab shows preliminary benefits for slowing geographic atrophy progression


Findings from a phase 2 randomized controlled trial (MAHALO) showed that an experimental intravitreal drug from Genentech offered moderate benefits in reducing progression of geographic atrophy.[Read More ] Source: Daily Dose of Eye Care
https://www.lvcenter4sight.com/lampalizumab-shows-preliminary-benefits-for-slowing-geographic-atrophy-progression/

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s